GSK disputes reports of all-Ireland ops review; WHO denies pharma influence on flu choices;

  @FiercePharma: Want a free pharma latte? Show your ID. Article | Follow @FiercePharma

> GlaxoSmithKline calls media reports of an overall review of operations in Ireland as "completely inaccurate", telling in-PharmaTechnologist that it is only evaluating its manufacturing plant in Cork. Report

> The head of the World Health Organization said her decisions about swine flu were not influenced by advisers' links to pharmaceutical companies, which were pointed out in a critical journal article this month. Report

> A federal judge threw out generics maker Wockhardt's claim that Sepracor misled patent examiners by covering up rat study data on sleep drug Lunesta. Report

> Moody's Investors Service lifted Watson Pharmaceuticals into investment-grade territory, citing the drugmaker's solid operating performance and cash-flow generation. Report

> Morningstar initiated credit coverage of AstraZeneca with a rating of AA, reflecting its positive view of the company's ability to repay debt even in the face of significant threats to its existing product portfolio. Report

> Forty-four percent of women research prescribed drugs using multiple sources before filling a script, a survey found, suggesting that marketing efforts must focus less on brand awareness and more on the post-script conversation. Report

> A new British study suggests that a standard treatment for gout, already in use for four decades, could be an effective and less expensive alternative to conventional drugs targeting chronic stable angina. Report

Biotech News

 @FierceBiotech: Forest Labs scoops up diabetes programs in $1.1B TransTech deal. Report | Follow @FierceBiotech    

 @JohnCFierce: Myriad is axing 21 staffers, suspending an HIV program and concentrating on cancer in restructuring. Report | Follow @JohnCFierce

> Discovery Labs hit with fresh setback on PhII Surfaxin failure. Article

> PharmAthene wins ruling in fight over $78M anthrax contract. Item

> OptiNose plans move to U.S. after gaining $48 million. Report

> Unigene names president, CEO. News

> Ambitious Regeneron unveils mixed PhIII results for gout drug. Story

Drug Delivery News

> Delcath can't woo investors with promising chemo delivery data. Story

> OptiNose plans move to US after gaining $48M for PhIII trials. Item

> Abilene offers incentives as it woos delivery tech start-up. Report

> Researchers target cancer cells with nanoparticles. Article

> Leonardo wins $2.5 million grant for delivery tech. News

> Team touts use of "glassified" proteins to improve biologics. Report

> Lasers used for painless injections. Story

Medical Device News

> St. Jude, hospitals to pay DOJ almost $4M. Report

> BD sells ophthalmic systems unit. Article

> Tornier files for $205M IPO. Item

> Teleflex begins hiring surge. Report

> Defibtech recalls DBP-2800 battery packs. News

And Finally... A new Health Affairs study argues that if the goal of U.S. healthcare legislation was to cover the most people at the lowest cost, the bill that passed was the best option that was also politically feasible. Report